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A B S T R A C T
Background: A ﬁxed combination of hawthorn and camphor (Korodin Herz-Kreislauf-Tropfen®) has been used in
the therapy of hypotension for decades. Although its eﬃcacy was evaluated in clinical trials, these studies have
not been critically assessed in meta-analyses.
Purpose: To systematically evaluate the eﬃcacy of a ﬁx combination of camphor and hawthorn extract
(Korodin®) on blood pressure and cognition compared to placebo, in a meta-analysis based on randomized
controlled trials (RCTs).
Study design: The meta-analysis was carried out following the PRISMA guidelines, using the PICO format, and it
was registered in the PROSPERO register.
Methods: The Cochrane Central Register of Controlled Trials, PubMed, Embase, and Web of Science databases
were searched for relevant studies. Placebo-controlled clinical studies involving adult patients receiving a ﬁx
combination of hawthorn extract and camphor were included. No language or publication year restrictions were
applied.
Results: Four randomized trials including a total of 221 patients were pooled for statistical analysis. According to
the present meta-analysis, the ﬁxed combination of hawthorn and camphor signiﬁcantly increases systolic and
diastolic blood pressure compared to placebo (p-values: 0.017 and 0.049, respectively) and had a beneﬁcial, but
not statistically signiﬁcant eﬀect on the cognitive performance in the connect-the-numbers test (p-value: 0.071).
Conclusion: Korodin® is an eﬀective and presumably safe complementary therapy for the treatment of hypo-
tension. Its blood pressure increasing eﬀect is conﬁrmed; however, the evidence supporting its use is very
limited. The optimum dose and duration of treatment is still unclear. The comprehensive evaluation of eﬃcacy
and safety is required in further, high-quality clinical studies, involving larger patient populations and com-
parable endpoints.
Introduction
By deﬁnition, hypotension is abnormally low blood pressure, with a
generally acknowledged upper limit of 90/60mmHg. Orthostatic hy-
potension is deﬁned as a drop of at least 20mmHg in systolic and/or
10mm Hg in diastolic blood pressure (BP) within 3min of standing or
https://doi.org/10.1016/j.phymed.2019.152984
Received 27 December 2018; Received in revised form 15 May 2019; Accepted 8 June 2019
Abbreviations: BP, blood pressure; CI, conﬁdence interval; DBP, diastolic blood pressure; GRADE, Grading of Recommendations Assessment; HR, heart rate; log RR,
Natural Logarithm of Risk Ratio; MAP, mean arterial pressure; PICO, P – patient, problem or population, I – intervention, C – comparison, control or comparator, O –
outcome; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; RCT, randomized controlled clinical trial; SBP, systolic blood pressure
⁎ Corresponding author.
E-mail address: csupor.dezso@pharmacognosy.hu (D. Csupor).
Phytomedicine 63 (2019) 152984
0944-7113/ © 2019 Elsevier GmbH. All rights reserved.
T
head-up tilt to at least 60° on a tilt table (Freeman et al., 2011). Ex-
siccosis, serious medical or surgical disorders, as well as taking certain
medications can result in hypotension. Signs and symptoms of hypo-
tension include dizziness, headache, nausea, palpitations, and fainting.
Beyond a decreased quality of life, chronic hypotension might decrease
cognitive performance as well. Serious hypotension is associated with a
high risk of morbidity and mortality, and in severe cases it can be life-
threatening.
The course of treatment depends on the exact type of hypotension
and on the underlying conditions. In some cases, life-style changes are
introduced to normalize blood pressure, and to avoid the sudden drop
of blood pressure. For the treatment of orthostatic hypotension, the
ﬁrst-line drug is midodrine, an alpha-adrenergic receptor agonist,
which is a frequently used vasopressor. In patients with orthostatic
hypotension, it elevates standing, sitting, and supine systolic and dia-
stolic blood pressure. Droxidopa, a synthetic precursor of nor-
epinephrine, is approved for the treatment of symptomatic neurogenic
orthostatic hypotension. Although several other pharmacological in-
terventions are also available, the quality of evidence on their coun-
terbalancing blood pressure drop is weak (Eschlböck et al., 2017).
Apart from synthetic drugs, plants and natural products with dif-
ferent mechanisms of actions are also used in the treatment of hypo-
tension. However, in most cases the eﬀectiveness of these products is
not suﬃciently established. In a small, single-blind, placebo-controlled
study, moderate doses (5.4 mg) of yohimbine were found to increase
systolic blood pressure of patients suﬀering from orthostatic hypoten-
sion (Jordan et al., 1998). Dihydroergotamine also exerts an alpha-
adrenergic receptor agonist activity, and based on human studies it
increases arterial blood pressure in orthostatic hypotension (Victor and
Talman, 2002).
A ﬁxed combination of Crataegus (hawthorn) extract and camphor
(Korodin Herz-Kreislauf-Tropfen®) has been used in patients with or-
thostatic hypotension and chronic hypotension for decades. In Germany
Korodin® is marketed as a medicine, and it contains a ﬂuid extract of
fresh Crataegus berries (DER: 1:1.3–1.5; extraction solvent: ethanol
93 V/V%, 97.3 g/100 g) and D-camphor (2.5 g/100 g) as active in-
gredients. In traditional medicine, both fruits and leaves and ﬂowers of
diﬀerent Crataegus species are used as cardioprotective agent and to
support cardiovascular function (Shikov et al., 2014). However, ac-
cording to the European Pharmacopoeia, Crataegi fructus may derive
only from Crataegus laevigata and C. monogyna. In modern phy-
totherapy, Crataegus drugs are used to alleviate various cardiovascular
conditions (e.g. arrhythmia, congestive heart failure). Interestingly,
most commercial products with conﬁrmed traditional use contain the
leaves and ﬂowers of the plants, and mono-preparations of Crategus
species are used for lowering blood pressure (Assessment report on
Crataegus spp., folium cum ﬂore, 2016). Randomized, double-blind,
placebo-controlled studies have conﬁrmed its antihypertensive eﬀects
(Tassell et al., 2010). According to the European Medicines Agency's
HMPC monograph, the use of Crataegus medicines containing 1–2 g of
comminuted herbal substance per dose is based on their ‘traditional use’
to relieve symptoms of temporary nervous cardiac complaints (e.g.
palpitations, perceived extra heart beat due to mild anxiety)
(European Union herbal monograph on Crataegus spp., folium cum ﬂore,
2016). Crataegus species are considered to be generally safe, but should
not be recommended during pregnancy and lactation because of the
lack of safety data. The topical use of camphor is known to increase
local skin and muscle blood ﬂow (Kotaka et al., 2014), but its eﬀects on
systemic blood pressure has not been studied in modern studies yet. The
cardiotonic eﬀect of camphor was observed in early studies
(Saratikov et al., 1964). Interestingly, inhaled camphor is reported to
decrease both heart rate and blood pressure (Eschlböck et al., 2017).
Nevertheless, the combination of hawthorn and camphor has been used
in the therapy to treat hypertension and the clinical eﬃcacy has been
assessed in human trials. The potential mechanism of action of this
combination is unknown.
Although the eﬀects of hawthorn and camphor combination on
blood pressure and cognitive performance have been studied in ran-
domized, controlled clinical trials (RCTs), their results are controversial
and have not been reassessed statistically in a meta-analysis. Therefore,
the aim of the present literature review and meta-analysis was to re-
assess and synthesize published evidence by systematically reviewing
the available literature data on the eﬃcacy of hawthorn-camphor
combination based on randomized, controlled clinical studies. The
following PICO (patients, intervention, comparison, outcome) format
was applied: P: hypotensive and normotensive adult patients; I: haw-
thorn extract and camphor in combination; C: placebo; and O: changes
in blood pressure and cognitive performance.
Methods
The meta-analysis was performed according to the PRISMA pro-
tocol, and it was registered in the International Prospective Register of
Systematic Reviews (PROSPERO) on 29 May 2018 (registration number
CRD42018095627).
Information sources and search strategy
Literature search was conducted until 24 September 2018, by using
the following search strategy: [("crataegus"[MeSH Terms] OR
"crataegus"[All Fields]) AND ("camphor"[MeSH Terms] OR
"camphor"[All Fields])] for PubMed; [('hawthorn'/exp OR hawthorn)
AND ('camphor'/exp OR camphor)] / [('crataegus'/exp OR crataegus)
AND ('camphor'/exp OR camphor)] for Embase; [crataegus AND cam-
phor / hawthorn AND camphor in Title, Abstract, Keywords in Trials]
for Cochrane Central Register of Controlled Trials; and [TOPIC: (cra-
taegus AND camphor / hawthorn AND camphor) Timespan: All years.
Indexes: SCI-EXPANDED, SSCI, A&HCI, ESCI.] for Web of Science. No
language, publication date or publication status restrictions were ap-
plied. The reference lists of all identiﬁed articles were inspected. Only
publicly available data were analysed, and neither the authors, nor the
manufacturers were contacted for additional information.
Eligibility criteria and study selection
Randomized, placebo-controlled trials evaluating the eﬀects of the
combination of hawthorn extract and camphor in adult hypotensive and
normotensive patients were included. Abstracts, case series, case re-
ports and articles not reporting numerical data on eﬃcacy were ex-
cluded. For reference management, Mendeley 1.17.9 was used. After
removing duplicates, the remaining records were screened for elig-
ibility based on the abstracts. The eligibility of the full texts of the re-
sulting records was assessed by two reviewers (T.K., D.C.) in-
dependently. In case of disagreement between reviewers, a third
reviewer (B.T.) was consulted.
Data extraction and synthesis of the results
Data collection was executed following the PRISMA guidelines.
Study characteristics and results were extracted by the two reviewers
independently. Discrepancies in extracted data were resolved by dis-
cussion. The following data items were extracted from the included
papers: study design, characteristics of the patient population and
sample size, intervention details, type of comparator(s), outcome
measures and overall results. Systolic and diastolic blood pressure va-
lues and the results of a cognitive performance test (connect-the-num-
bers test) were extracted as outcome measures. Discrepancies in ex-
tracted data were resolved by discussion between the two reviewers.
Risk of bias analysis
The risk of bias was analysed by two of the authors (B.T., D.C.),
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using the Cochrane Collaboration tool which includes the following
domains: random sequence generation, allocation concealment,
blinding of participants and personnel, blinding of outcome assessment,
incomplete outcome data, selective reporting and other scores of bias.
For each domain, studies were judged to have a high (red), unclear
(yellow) or low (green) risk of bias (see Supplementary Fig. S1).
Disagreement was resolved by discussion. Risk of bias ﬁgures were
prepared by using the RevMan 5 statistical program (Higgins JPT and
Green S, 2011).
Quality of evidence
The Grading of Recommendations Assessment, Development and
Evaluation (GRADE) was used for estimating the quality of evidence of
all outcomes assessed (Guyatt et al., 2008).
Statistical analysis
The Hedges’ g statistic was applied to measure eﬀect size for the
diﬀerence between means, as it adjusts for bias in small samples by
weighting the pooled standard deviations by sample size
(Hedges, 1981). p-values of less than 0.05 were considered as indicators
of signiﬁcance. Data were graphically presented using forest plots.
Heterogeneity was assessed using the Cochran's Q test
(Cochran, 1954) and Higgins’ I2 indicator (Higgins et al., 2003), where
Q exceeds the upper tail critical value of Chi-square on k− 1 degrees,
and I2 represents the percentage of eﬀect size heterogeneity that cannot
be explained by random chance. A p-value of less than 0.1 was con-
sidered suggestive of signiﬁcant heterogeneity. According to the Co-
chrane Handbook (Higgins JPT and Green S, 2011), I2 values of
25–50%, 50–75% and over 75% correspond to low, moderate and high
degrees of heterogeneity, respectively. For statistical analysis we ap-
plied the ﬁxed-eﬀects model (Mantel-Haenszel method) (Mantel and
Haenszel, 1959) on homogeneous results, whereas for heterogeneous
results the random-eﬀects model (DerSimonian-Laird method)
(DerSimonian and Laird, 1986) was employed. All the statistical ana-
lyses were performed using the Comprehensive Meta-Analysis software
(version 3, Biostat Inc., Englewood, NJ, USA).
Results
Study selection
Literature search was conducted in Embase, PubMed, the Cochrane
Central Register of Controlled Trials and Web of Science databases,
with Crataegus/hawthorn and camphor as search terms. After removing
duplicates, 30 potentially relevant reports were collected (see excluded
studies in Table 1S, Supporting Information). Eligible RCTs were se-
lected according to the ﬂow chart presented in Fig. 1.
After screening the abstracts, 8 publications were retrieved for full-
text screening (Belz et al., 2002; Belz and Loew, 2003; Erfurt et al.,
2014; Hempel et al., 2005; Kroll et al., 2005; Schandry et al., 2018;
Schandry and Duschek, 2008; Werner et al., 2009). Hempel et al. re-
ported an epidemiological retrospective cohort study, not an RCT;
therefore, it was not included in our meta-analysis (Hempel et al.,
2005). Nevertheless, the authors of this study concluded that Korodin®
was safe and eﬀective in the treatment of orthostatic hypotension. One
review article (Belz and Loew, 2003) cited the results of a double-blind
randomized clinical trial which was only reported as a conference ab-
stract (Herrmann et al., 1996). According to this review (Belz and
Loew, 2003) Herrmann et al. conducted a trial in which healthy male
volunteers received sequential doses of camphor-hawthorn extract, and
the administration of Korodin® increased baseline mean arterial pres-
sure (ANOVA p< 0.001). However, this article was also excluded since
it did not fulﬁl the inclusion criteria.
In total, seven studies, which were reported in six articles, were Ta
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selected for the qualitative analysis. Of these seven studies, three RCTs
were ﬁnally not included in the statistical analysis. In a recently pub-
lished paper, Schandry et al. studied the eﬀects of Korodin® on ado-
lescents (Schandry et al., 2018). Because the subjects in this study were
not adults, it was not included in the quantitative analysis. In the RCT
conducted by Belz et al. the clinical assessment substantially diﬀered
from that in other studies, hence it was not possible to compare the
results of this study to the results of the other clinical trials (Belz et al.,
2002). Another study failed to report all the essential data numerically,
i.e. the means and standard deviations (SD) for systolic blood pressure
(SBP), diastolic blood pressure (DBP), and mean arterial pressure
(MAP) before and after the administration of placebo and Korodin®
were shown only graphically; therefore, the results of this trial could
not be included in the quantitative analysis (Kroll et al., 2005). Finally,
three articles, reporting 4 studies with 221 patients were assessed in the
quantitative meta-analysis (Erfurt et al., 2014; Schandry and Duschek,
2008; Werner et al., 2009).
Risk of bias assessment
Overall, the methodical quality of the trials included in our ﬁnal
quantitative analysis was reckoned to be acceptable (Erfurt et al., 2014;
Schandry and Duschek, 2008; Werner et al., 2009), mostly with a low or
unclear risk of bias (see Supplementary Figures S1 and S2). One paper
reported on two trials (Schandry and Duschek, 2008), for which the
methodology was similar but not exactly the same; therefore, the risk of
bias analysis for these studies were performed separately. The ﬁrst
study was performed from 8 November 2006 to 31 November 2006,
and it is marked as Schandry 2008a in Supplementary Figures S1 and
S2; the second study, performed from 5 November 2007 to 5 December
2007, is marked as Schandry 2008b in Supplementary Figures S1 and
S2.
Selection bias, i.e. random sequence generation and allocation
concealment was considered to be high in the study reported by Erfurt
et al., because the patients were randomized according to the sequence
of their appearance (Erfurt et al., 2014). In both studies performed by
Schandry and Duschek computer generated randomization plan was
used; thus the selection bias of these studies was reckoned to be low
(Schandry and Duschek, 2008). Werner et al. failed to describe the
methods used for random sequence generation, allocation and blinding
of outcome assessment; therefore the selection and detection bias of this
study remains unclear (Werner et al., 2009).
Performance bias was unclear in all the included studies, because
none of them described properly whether or not the intervention and
Fig. 1. PRISMA 2009 ﬂow diagram for the identiﬁcation of relevant studies.
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the placebo were identical in shape, size, colour and odour. Detection
bias diﬀered between the studies. Erfurt and colleagues reported that
unblinding occurred at data analysis; therefore this study has a high risk
of detection bias. The other studies had an unclear risk of detection
bias, because it was unclear from the papers whether outcome assess-
ment was performed in a blinded manner or not.
All of the studies showed a low risk of attrition bias and an unclear
risk of other types of bias. Reporting bias was reckoned to be high only
in the study performed by Erfurt et al., because the results of the digit
symbol test were not reported (Erfurt et al., 2014); nevertheless, the
other studies were judged to have a low risk of reporting bias.
Due to the low number of studies, publication bias was not assessed
by Egger's test, nor by funnel plots.
Study characteristics
All of the studies included in the meta-analysis were conducted by
German authors and were presumably carried out in Germany (Erfurt
et al., 2014; Schandry and Duschek, 2008; Werner et al., 2009). All
were randomized, placebo-controlled, double blind studies. The study
drug was Korodin® in all cases. All studies were supported by Robugen
GmbH either by providing the test substances or by the ﬁnancial re-
muneration of the participants. The papers were published between
2008 and 2014. The main characteristics of the included studies are
summarized in Table 1. The paper by Schandry and Duschek reports on
two clinical trials (performed in 2006 and 2007, respectively). In both
trials, women aged 18–40 years with hypotension SBP < 100mmHg
were recruited, and the design of the studies were practically uniform.
Exclusion criteria included pregnancy, hypothyroidism, severe physical
illness, psychiatric disorders, psychoactive therapy, and taking cardio-
vascular medicine(s) or Korodin®. Each participant received a single
dose of 25 drops of Korodin® or placebo. The main diﬀerence between
the two trials was that in the ﬁrst one three cognitive tests (attentional
performance test, connect-the-numbers test, alertness test), whereas in
the second one two tests (connect-the-numbers test, digit symbol test)
were performed. Blood pressure values (SBP and DBP) were measured
prior to and after the application of Korodin® and placebo, similarly to
performing the cognitive tests before and after the treatment. The time
between Korodin® application and blood pressure reading was 3 min in
the ﬁrst study, whereas it was not speciﬁed in the other one carried out
in 2007 (Schandry and Duschek, 2008).
Werner and colleagues enrolled 80 normotensive female partici-
pants (50–80 years). Those taking medicines that aﬀect the cardiac
system were excluded. The applied dose of Korodin® was 25 drops
(single administration). SBP and DBP values were measured before and
after the administration of the active treatment or placebo. In this
study, the connect-the-numbers test and the digit symbol test were used
to assess treatment eﬀects on cognitive performance. Participants under
psychopharmacological treatment (n=3) were excluded from the
cognitive tests, and regarding the connect-the-numbers test, those
whose processing time was > 115 s were excluded from the analysis.
MAP, continuous MAP and heart rate were also determined.
Erfurt and colleagues studied the eﬀects of 4× 20 drops of Korodin®
in 54 healthy young adults (18–40 years, males and females). Exclusion
criteria included aﬀective disorders, serious chronic diseases, history of
substance abuse, severe cognitive disorders, pregnancy and breast-
feeding. The study drug or placebo was administered 4 times, with
10min intervals. BP was measured 2 min after each administration. For
comparability, only data obtained after the ﬁrst administration were
included in our meta-analysis. Cognitive performance was assessed
using the d2 Test of Attention and the digit symbol test.
Outcomes
Excluded studies
Although three studies were excluded from the meta-analysis, the
results of these may also contribute to the whole picture of the clinical
eﬃcacy of Korodin®. Belz et al. conducted two controlled, randomized,
double-blind, crossover studies to assess the eﬀects of three diﬀerent
single dosages (5 drops, 20 drops and 80 drops) of Korodin® in a total of
48 young patients with orthostatic hypotension (average age: 25.6 and
27.3 years, respectively, in the two studies) (Belz et al., 2002). Their
paper reports the results of these two separate trials, which were of the
same design (except that phlebotomy was performed in the ﬁrst study);
however, the primary outcome measure was diﬀerent in the two stu-
dies, being the change in SBP in the ﬁrst one, and the change in MAP in
the second one. Blood pressure (including SBP, DBP and MAP values)
and HR were measured pre- and posttreatment, 1, 3 and 5 min after the
administration of Korodin® or placebo, according to a tilt table test
protocol. Accordingly, patients were lying on a table for 15 min before
the table was lifted at an 80° angle before HR and BP measurements to
assess the eﬀects of Korodin® on orthostatic hypotension. Since no
statistically signiﬁcant eﬃcacy of the treatment on the primary out-
comes was detected in either studies, the authors pooled the data for a
combined analysis. The combined analysis revealed a signiﬁcant eﬀect
of the 80-drop-dose on increasing MAP 1min after administration, as
well as on increasing SBP after 1min and DBP at all three posttreatment
time points (1, 3 and 5 min). There was a trend for correlation between
dosage and eﬃcacy, with the dose of 80 drops being the most eﬀective
(1min post-administration, MAP, SBP and DBP increased by 4.48, 6.21
and 3.38mmHg, respectively) (Belz et al., 2002).
Kroll et al. studied the eﬀects of a single dose of 25 drops, and then 7
consecutive days of treatment with Korodin® at a daily dose of 3×25
drops in 38 elderly (>50 years) patients with orthostatic hypotension
in a randomized, double-blind, placebo-controlled setting (Kroll et al.,
2005). After a single application, the median decrease in MAP after
standing up was 11.4 mmHg for Korodin® and 14.0 mmHg for placebo.
Compared to baseline, the median MAP improved by 4.3 mmHg for
Korodin® and 0.3mmHg for placebo. However, regarding the single-
dose application, these changes did not correspond to a statistically
signiﬁcant diﬀerence between the active and placebo arms. After 1
week of daily treatment the decrease in median MAP after standing up
was 9.3 mmHg for Korodin® and 13.3 mmHg for placebo (corresponding
to an improvement of 5.9mmHg and 1.6mmHg, respectively, com-
pared to baseline), demonstrating a statistically signiﬁcant diﬀerence in
the eﬃcacy of Korodin® vs. placebo. Regarding treatment eﬀects on
quality of life, assessed by an SF-12 questionnaire focusing on symp-
toms frequently associated with orthostatic hypotension, the active
treatment was found to be superior in 5 over 7 items; however, the
statistical analysis of these data was not published in the paper
(Kroll et al., 2005).
A double-blind, randomized, placebo-controlled study by Schandry
et al. aimed to assess the eﬃcacy of a single dose of 20 drops of
Korodin® on BP and cognitive performance (using the connect-the-
numbers test and the digit symbol test) in 200 hypotensive adolescents
(SBP < 118mmHg in boys and < 110mmHg in girls) (Schandry et al.,
2018). SBP, DBP and MAP values increased signiﬁcantly after the ad-
ministration of 20 drops of Korodin® compared to placebo (p < 0.001,
p=0.004 and p < 0.001, respectively). Heart rate did not change
signiﬁcantly, and no diﬀerence in cognitive performance compared to
baseline were detected based on the tests performed (Schandry et al.,
2018).
Included studies
In the included studies the primary outcomes were changes in SBP
and DBP from baseline (measured by the Riva-Rocci method and ex-
pressed in mmHg) (Table 2). MAP was also calculated in two studies
(Erfurt et al., 2014; Werner et al., 2009); however, this was not used as
a measure of eﬃcacy, since it is derived from SBP and DBP. Increases in
these values directly reﬂect the eﬃcacy of hypotension's therapy.
Cognitive tests were used to assess the potentially favourable eﬀects of
Korodin® on reduced cognitive performance which might be related to
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chronic hypotension. These tests focus on alertness, reaction time,
processing speed, rule compliance, quality of performance, visual-
motor coordination, and short-term visual memory. Three of the
quantitatively analysed studies applied the connect-the-numbers test,
hence these results were included in our meta-analysis. In the connect-
the-numbers test, 90 numbers are arranged in an arbitrary sequence.
Participants are asked to connect these numbers in the correct sequence
as quickly as possible. The test comprises 4 sheets (4× 90 numbers).
Werner et al. deﬁned exclusion criteria (processing time >115 s, psy-
chopharmacological treatment) for the applicability of this test or being
included in this speciﬁc analysis (Werner et al., 2009), whereas Erfurt
et al. deﬁned no such restrictions (Erfurt et al., 2014).
Eﬀects of Korodin® on blood pressure
In the study by Erfurt et al., 20 drops of Korodin® or placebo was
administered to patients, 4 times in 10min intervals. The active treat-
ment was superior to placebo in terms of increasing SBP at the ﬁrst 3
substance administrations, and in increasing DBP after the ﬁrst ad-
ministration (Erfurt et al., 2014). Werner et al. administered 25 drops of
Korodin®/placebo to their patients, and found that HR and MAP in-
creased signiﬁcantly at 2 and 3 min after administration of a single dose
(Werner et al., 2009). In the two studies published by Schandry and
Duschek, there was a signiﬁcant increase in SBP in both studies,
whereas DBP decreased signiﬁcantly in the verum group (25 drops of
Korodin®) compared to placebo only in study I (Schandry and
Duschek, 2008). In summary, all the four included trials assessed the
eﬀects of Korodin® on blood pressure, and the authors of each study
concluded that the combined preparation increases blood pressure
compared to placebo.
For the quantitative meta-analysis of data regarding the eﬀects on
DBP, a ﬁxed-eﬀects model (Q=3.192, df = 3, p=0.363,
I2 = 6.009%) was applied: Hedges’ g=0.269; lower limit of 95% CI
[LL]: 0.001, upper limit of 95% CI [UL]: 0.538, P-value: 0.049 (Fig 2).
For the statistical analysis of the results regarding the eﬀects on SBP, a
random-eﬀects model was employed: Q=7.691, df = 3, p=0.053,
I2 = 60.995%. The results of our meta-analysis support that Korodin®
increases SBP: Hedges’ g=0.546; lower limit of 95% CI [LL]: 0.099,
upper limit of 95% CI [UL]: 0.992, p-value: 0.017 (Fig 3).
Eﬀects of Korodin® on cognitive functions
In the study by Schandry and Duschek, the eﬃcacy of Korodin® was
reﬂected in an improved cognitive performance of treated participants
compared to placebo, in the connect-the-numbers test and the digit
symbol test, but not in the alertness test and the attentional perfor-
mance test (Schandry and Duschek, 2008). Erfurt et al. observed no
eﬀects attributable to Korodin® in the digit symbol test; however, the d2
test of attention revealed signiﬁcant eﬃcacy at certain measurement
points (Erfurt et al., 2014). Based on the ﬁndings of Werner et al.,
Korodin® treatment signiﬁcantly improved cognitive performance in the
connect-the-numbers test and in the digit symbol test (Werner et al.,
2009).
Three trials reported the results for the connect-the-numbers test;
therefore, it was possible to perform a meta-analysis of these data.
Applying a ﬁxed-eﬀects model (Q=0.072, df = 2, p=0.965, I2= 0%)
in our statistical analysis, we have conﬁrmed that Korodin® does not
improve signiﬁcantly the cognitive function of treated patients (Hedges’
g=0.276; lower limit of 95% CI [LL]: −0.024, upper limit of 95% CI
[UL]: 0.576, p-value: 0.071 (Fig 4).
Quality of evidence
The grade of evidence of our statements was quantiﬁed with the
GRADE approach (Table 3). Since only randomized controlled studies
very included;the baseline grade of evidence was considered high.
However, the authors think that bias-free high grade of evidence is only
obtainable with analysing a large number of high quality randomized
controlled studies. To assess the grade of evidence we considered ﬁve
downgrading items (i.e. limitations in the design and implementation,
indirectness, heterogeneity, imprecision, and publication bias).
Table 2
Outcomes of the RCTs included in the meta-analysis.
First author (year) Group Dose Sample size Systolic blood
pressure before
treatment
Systolic blood
pressure after
treatment
Diastolic blood
pressure before
treatment
Diastolic blood
pressure after
treatment
Connect the
numbers test
before
Connect the
numbers test
before treatment
(mean± SD,
mmHg)
(mean± SD,
mmHg)
(mean± SD,
mmHg)
(mean± SD,
mmHg)
treatment (mean
± SD, s)
(mean± SD, s)
Erfurt et al. (2014) Korodin® 20 dropsb 38 109.8 ± 12.1 115.1 ± 11.9 73.7 ± 8.5 76.8 ± 8.1 – –
Placebo 15 115.2 ± 14.9 116.9 ± 15.3 72.1 ± 6.9 72.6 ± 9.4 – –
Werner et al. (2009 Korodin® 25 drops 40 121.78 ± 16.4 127.23 ± 17.21 81.48 ± 7.83 86.53 ± 8.94 84.12 ± 15.11 71.93 ± 13.58
Placebo 40 123.08 ± 19.38 125.7 ± 19.23 80.35 ± 10 81.68 ± 10.14 83.45 ± 15.18 74.6 ± 14.82
Schandry (2008aa) Korodin® 25 drops 19 97.65 ± 5.11 102.25 ± 7.28 62.2 ± 6.89 67.75 ± 8.25 67.7 ± 12.8 58.8 ± 9.8
Placebo 21 96.6 ± 4.83 95.8 ± 6.93 60.84 ± 5.53 62.37 ± 6.7 60.4 ± 9.4 54.4 ± 8.1
Schandry (2008ba) Korodin® 25 drops 24 99.08 ± 5.59 107.25 ± 7.24 64.46 ± 6.58 66.42 ± 5.75 63.8 ± 14.5 53.9 ± 10.8
Placebo 24 101.67 ± 7.38 102.17 ± 6.18 63.79 ± 6.62 66.71 ± 6.29 59.1 ± 11.1 52.4 ± 9.3
a The two studies reported in one paper are named as Schandry (2008a) for the trial performed in 2006, and Schandry (2008b) for the trial performed in 2007.
b For comparability, the data related to the ﬁrst administration were included in our meta-analysis.
Fig. 2. The eﬀects of the combined camphor-hawthorn extract on diastolic blood pressure in a ﬁxed-eﬀects model (n=4).
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The ﬁnding that Korodin® increases SBP and DBP is supported by
low quality evidence. Since selection, detection and reporting biases
were considered to be high in the study of Erfurt et al., we have
downgraded the level of evidence with one level (Erfurt et al., 2014).
Moreover, publication bias might be suspected because the published
evidence includes only a few small trials. Therefore, we have decided to
downgrade the level of evidence with one more level. Overall, the blood
pressure increasing eﬀects of Korodin® is supported by low quality of
evidence, i.e. further research is very likely to have an important impact
on our conﬁdence in the estimate of eﬀect and is likely to change the
estimate.
It is supported by moderate quality of evidence that Korodin® has a
beneﬁcial, but not statistically signiﬁcant eﬀect on the cognitive per-
formance. We downgraded the high quality evidence due to high
probability of publication bias, i.e. only three trials involving 168 pa-
tients studied the eﬀects of Korodin® on the cognitive performance.
Safety
In the study by Belz et al., Korodin® was well tolerated and no ad-
verse eﬀects attributable to the treatment were reported. Clinical ex-
aminations and laboratory tests revealed no clinically relevant patho-
logical ﬁndings; however, no detailed results were published
(Belz et al., 2002). In the studies involving adolescents, no adverse
events were reported (Schandry et al., 2018). In the study involving
patients older than 50 years, only one adverse event was reported,
which was not serious and was not related to the treatment (shoulder
ache) (Kroll et al., 2005). Erfurt et al. did not report any adverse eﬀects
(Erfurt et al., 2014). Unfortunately, in two papers, no safety data were
reported (Schandry and Duschek, 2008; Werner et al., 2009).
Discussion
Although hypotension is strongly associated with morbidity and
mortality, its treatment options are much more limited than those of
hypertension (Eschlböck et al., 2017). Besides a few synthetic drugs,
there is only one combined natural product available as a medicine for
the treatment of hypotension. The ﬁxed combination of Crataegus ex-
tract and camphor (Korodin®) was introduced to the German market in
1927, and it is still used in Germany to relieve symptoms of orthostatic
and chronic hypotension (Kroll et al., 2005). The present meta-analysis
was designed to synthesize the currently available evidence for this
product, and it is known to be the ﬁrst systematic review and meta-
analysis on this topic.
Based on a comprehensive literature search, four RCTs were iden-
tiﬁed, which included 221 adults. The eﬀects of Korodin® on the out-
comes tested in RCTs are summarized in Table 2. Few publications
reported on the same outcomes, and there were also diﬀerences in the
posology of the study drug. Moreover, the setting of the trials was not
uniform; therefore, the forest plots are short. Because of the scarce of
trials reporting on the same outcomes it was not possible to properly
assess publication bias by the Egger's tests or by funnel plots. Based on
SBP and DBP results the combined preparation is conﬁrmed to ame-
liorate hypotension, but its eﬀects on cognitive performance is not
signiﬁcant. Therefore, based on our meta-analysis, the superiority of the
combination of Crataegus extract and camphor over placebo in the
treatment of hypotension is still not undoubtedly justiﬁed. These results
are in line with the expectations reasoned by the low number of trials
focusing on Korodin®.
Limitations of our literature review and meta-analysis are largely
related to the original studies. All the included trials were carried out in
Germany, and there is a clear overlap between the authors of the pa-
pers. All of the quantitatively analysed trials were published within a
relatively short time period, between 2008 and 2014. Because of the
small number of participants, normotensive and hypotensive patients
were analysed combined in our meta-analysis, yielding an in-
homogeneous patient population, and it is possible that baseline blood
pressure readings could have inﬂuenced the overall results.
Our meta-analysis, however, conﬁrms the relative safety of
Korodin®, since the incidence of adverse events was not statistically
diﬀerent between the actively treated and the placebo groups.
However, the number of patients involved in the reviewed trials are
relatively low; hence a comprehensive evaluation of safety is required
through further clinical studies and pharmacovigilance activities, which
is indeed an unmet need, regarding that Korodin® has been used for
over 90 years.
Fig. 3. The eﬀects of the combined camphor-hawthorn extract on systolic blood pressure in a random-eﬀects model (n=4).
Fig. 4. The eﬀects of the combined camphor-hawthorn extract on cognitive performance in a ﬁxed-eﬀects model (n=3).
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Conclusion
Our meta-analysis supports that Korodin® can be regarded as an
eﬀective complementary therapy for the treatment of hypotension;
however, there is a need for further trials to improve the quality of the
body of evidence. The optimum dose and duration of treatment is still
unclear. In the included studies, Korodin® was well-tolerated and its
adverse eﬀect proﬁle did not diﬀer from that of placebo. According to
our meta-analysis, the combination of Crataegus extract and camphor
increases SBP and DBP; however, its eﬀects on cognitive performance is
not signiﬁcant. As a conclusion, there is a clear need for further high-
quality trials involving larger patient populations, and examining the
eﬀects of diﬀerent, preferably higher doses of the combined prepara-
tion. Also it would be essential to apply comparable endpoints to assess
the eﬃcacy of Korodin® with a lower risk of bias. In the future, further
trials may allow the analysis of the eﬀects of Korodin® in dose-based
subgroups. Our meta-analysis supports the long-standing use of
Korodin; nevertheless, it highlights the lack of clinical data regarding
natural products.
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